CanCOG®: Pilot Trial of Cognitive Rehabilitation for Cancer Survivors (CanCOG®)
7. August 2026 aktualisiert von: Sofia Alexandra Marques Fernandes, Aveiro University
CanCOG® - Cognitive Rehabilitation in Cancer: A Protocol for a Multicenter Pilot Randomized Controlled Trial With Non-central Nervous System Cancer Survivors
Cancer-related cognitive impairment (CRCI) affects a large proportion of non-central nervous system cancer survivors and can negatively impact cognitive functioning and daily life. Cognitive rehabilitation has shown promising results in addressing these difficulties. The goal of this pilot randomized controlled trial is to evaluate the feasibility, acceptability, and preliminary efficacy of the CanCOG®- Cognitive Rehabilitation in Cancer program in Portuguese adult cancer survivors with CRCI.
Adult non-central nervous system cancer survivors (n=60) will be randomly assigned to receive either the CanCOG® intervention or treatment as usual.
CanCOG® is a structured cognitive rehabilitation program designed to help cancer survivors manage cognitive difficulties through cognitive training exercises, psychoeducation, and compensatory strategy training. The program consists of six weekly sessions of 1 hour and 30 minutes each, delivered over six consecutive weeks. Sessions are administered in person in small groups (3-9 participants) and are led by a trained professional.
The main focus of the study is to assess feasibility outcomes, including recruitment, retention, adherence to the intervention, and completion of study assessments, as well as acceptability and participant satisfaction.
The study will also explore preliminary effects of the intervention on cognitive functioning (both perceived and objective), symptoms of anxiety and depression, and quality of life. Participants will complete assessments at baseline (2 weeks after the intervention), 2 weeks after the intervention, and at 3- and 6-month follow-ups. Some participants (10-15) will also take part in interviews to provide feedback on their experience with the program.
Studienübersicht
Status
Status
Noch keine Rekrutierung
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Cancer-related cognitive impairment (CRCI) is a frequent consequence of cancer and its treatments in non-central nervous system survivors and has been associated with persistent difficulties in multiple cognitive domains, including attention, memory, and executive functioning.
Cognitive rehabilitation approaches aim to improve cognitive functioning and promote the use of compensatory strategies to support daily functioning in individuals experiencing CRCI. The CanCOG® program is a structured group-based cognitive rehabilitation intervention delivered by trained professionals and incorporating cognitive training exercises, psychoeducation, and strategy training.
This study is a pilot randomized controlled trial designed to inform the feasibility and acceptability of the intervention and study procedures, as well as to provide preliminary evidence regarding potential intervention effects.
The intervention consists of six weekly in-person group sessions (1 hour and 30 minutes each), delivered over six consecutive weeks in small groups of 3 to 9 participants.
Outcomes will be assessed using a comprehensive neuropsychological and psychosocial evaluation battery covering global cognition, memory, attention, executive functioning, psychological distress, and quality of life, using validated instruments. Assessments will be conducted at baseline, post-intervention, and at 3- and 6-month follow-up time points.
Data will be collected in Portuguese healthcare units. The study has been submitted to and approved by the relevant Ethics Committee, and complies with the General Data Protection Regulation (GDPR).
Studientyp
Studientyp
Interventionell
Einschreibung (Geschätzt)
Einschreibung
60
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
Studienkontakt
- Name: Sofia A Marques-Fernandes, M.Sc.
- Telefonnummer: 00351 965252831
- E-Mail: sofiafernandes6@ua.pt
Studienorte
-
-
-
Aveiro, Portugal, 3810-193
- University of Aveiro
-
Kontakt:
- Sofia A Marques-Fernandes, M.Sc.
- Telefonnummer: 00351965252831
- E-Mail: sofiafernandes6@ua.pt
-
Hauptermittler:
- Sofia A Marques-Fernandes, M.Sc.
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Adults aged 18 to 65 years whose native language is European Portuguese;
- Diagnosis of cancer not involving the central nervous system (non-CNS cancer);
- Disease stage I to III;
- Completion of primary cancer treatment at least 6 months and no more than 5 years prior to enrollment (with the exception of ongoing hormone therapy and immunotherapy);
- Score < 51 on the Perceived Cognitive Abilities subscale of the FACT-Cog v3. Stable psychiatric and neurological medication regimen for at least 3 months prior to enrollment;
- Educational level equal to or higher than the 3rd year of primary education;
- Ability to read and write in Portuguese and provide informed consent to participate.
Exclusion Criteria:
- Diagnosis of current severe psychiatric disorders (e.g., schizophrenia, psychosis, bipolar disorder, major depressive disorder, or attention-deficit/hyperactivity disorder);
- Diagnosis of communication disorders;
- Diagnosis of neurodevelopmental disorders or other severe medical conditions (e.g., history of stroke, encephalitis, dementia or neurodegenerative disease, epilepsy, or traumatic brain injury);
- Presence of metastases or other tumors;
- History of substance abuse (alcohol or drugs);
- Current or prior participation in another cognitive rehabilitation intervention.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
2
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Cognitive rehabilitation intervention
Participants allocated to this arm will receive the CanCOG® cognitive rehabilitation intervention in addition to usual care.
Following baseline assessment (2 weeks before the intervention), participants will attend the intervention over a 6-week period and complete study assessments 2 weeks after the intervention and at 3- and 6-month follow-up time points.
Participants will be asked to complete neuropsychological and psychosocial assessments at each evaluation point.
A subset of participants (10-15) may also be invited to participate in a semi-structured interview to explore the acceptability of the intervention, perceived benefits, barriers to participation, and overall satisfaction with the program and study procedures.
|
CanCOG® is a structured cognitive rehabilitation program designed for cancer survivors experiencing cancer-related cognitive impairment (CRCI).
The intervention is delivered in person in small groups of 3 to 9 participants by a trained professional and consists of six weekly sessions of 90 minutes each over six consecutive weeks.
The program combines psychoeducation about CRCI, cognitive training exercises targeting domains such as attention, memory, and executive functioning, and compensatory strategy training to support everyday cognitive functioning and self-management of cognitive difficulties.
|
|
Kein Eingriff: Treatment-as-usual
Participants allocated to this arm will continue to receive the usual care and support available through their healthcare providers and will not receive the CanCOG® intervention during the study period.
Participants will complete the same schedule of neuropsychological and psychosocial assessments as the intervention group at baseline, post-intervention, and at 3- and 6-month follow-up time points.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility - Screening rate
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups.
|
Screening rate will be assessed as the proportion of potentially eligible cancer survivors who undergo eligibility screening.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups.
|
|
Feasibility - Eligibility rate
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
The eligibility rate will be assessed as the proportion of screened individuals who meet the eligibility criteria.
Reasons for ineligibility will be documented whenever available.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
|
Feasibility - Consent rate
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups.
|
Consent rate will be assessed as the proportion of eligible individuals who provide informed consent.
Reasons for refusal to participate will be documented whenever available.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups.
|
|
Feasibility - Retention rate
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
Retention rate will be assessed as the proportion of participants who remain enrolled until study completion.
Reasons for withdrawal will be documented whenever available.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
|
Feasibility - Assesment completion rate
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
Assessment completion rate will be assessed as the proportion of participants completing assessments at each assessment time point.
Reasons for missed assessments will be documented whenever available.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
|
Feasibility - Intervention adherence
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
Intervention adherence will be assessed as the proportion of intervention sessions attended by participants allocated to the intervention group.
Reasons for missed sessions will be documented whenever available.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
|
Feasibility - Intervention fidelity
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
Intervention fidelity, the extent to which the intervention is delivered according to the intervention manual and session plans, will be assessed through facilitator-completed fidelity checklists.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups
|
|
Acceptability - Participant retention and intervention adherence
Zeitfenster: Baseline ( 2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Acceptability of the intervention will be assessed using participant retention (proportion of participants who remain enrolled until study completion) and intervention adherence (proportion of intervention sessions attended by participants allocated to the intervention group).
|
Baseline ( 2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Acceptability - Qualitative feedback
Zeitfenster: Post-intervention (2 weeks after)
|
Acceptability will be assessed through semi-structured interviews conducted with 10-15 participants from the intervention group. Interviews will explore participants' perceptions of the intervention content, format, duration, group delivery, perceived usefulness, and barriers or facilitators to participation. |
Post-intervention (2 weeks after)
|
|
Acceptability - ACRIS-CS
Zeitfenster: Baseline (2 weeks before intervention) and post-intervention (2 weeks after).
|
Acceptability will also be assessed through the Acceptability of Cognitive Rehabilitation Interventions Survey-Cancer Survivors (ACRIS-CS).
This 11-item instrument evaluates participants' perceptions of the intervention's acceptability, including its perceived usefulness, appropriateness, and overall satisfaction.
Higher scores indicate greater acceptability of the cognitive rehabilitation intervention.
|
Baseline (2 weeks before intervention) and post-intervention (2 weeks after).
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Perceived cognitive functioning
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2weeks after), 3-month and 6-month follow-ups.
|
Perceived cognitive functioning will be assessed with the Functional Assessment of Cancer Therapy-Cognitive Function version 3 (FACT-Cog v3).
It consists of a 37-item self-report questionnaire composed of four subscales: Perceived Cognitive Impairments (CogPCI), Perceived Cognitive Abilities (CogPCA), Comments from Others (CogOth), and Impact on Quality of Life (CogQoL).
The higher the score, the better the perceived functioning.
|
Baseline (2 weeks before intervention), post-intervention (2weeks after), 3-month and 6-month follow-ups.
|
|
Objective cognitive functioning (Global cognition)
Zeitfenster: Baseline (2 weeks before intervention), Post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Global cognition will be assessed using the Montreal Cognitive Assessment (MoCA).
The instrument's scores range from 0 to 30, with lower scores indicating poorer cognitive performance.
|
Baseline (2 weeks before intervention), Post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Objective cognitive functioning (Verbal learning and memory)
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
The test includes immediate recall across five learning trials, delayed recall after 30 minutes, and a recognition trial, allowing the assessment of acquisition, retention, and recognition processes.
Lower scores indicate poorer performance.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Objective cognitive functioning (Attention and processing speed)
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Attention and processing speed will be assessed with the Trail Making Test Part A (TMT-A) and D2 Test of Attention. TMT- A: Performance is based on completion time and errors. Higher adjusted scores correspond to better performance. D2 Test of Attention: The scoring of this test provides the following results: Total Characters Processed, Total Correct Responses, Total Efficiency and Concentration Index. Higher scores suggest better performance. |
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Objective cognitive functioning (Executive functioning and cognitive flexibility)
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Executive functioning and cognitive flexibility will be assessed using the Trail Making Test Part B (TMT-B).
Performance is based on completion time and errors.
Higher adjusted scores correspond to better performance.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Objective cognitive functioning (Working memory)
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Working memory will be assessed using the Wechsler Adult Intelligence Scale's (WAIS) - Digit Span subtest.
It consists of three components: Digit Span forward, Digit Span Backward, and Digit Span sequencing.
Higher scores indicate better performance.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Objective cognitive functioning (Verbal fluency)
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Verbal fluency will be assessed with the Verbal Fluency Test (VFT).
For the VFT, participants are required to remember, in one minute, the maximum number of words possible started by a specific letter or belonging to a specific category.
A higher number of words recalled indicates better cognitive performance.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Objective cognitive functioning (Inhibitory control)
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Inhibitory control will be assessed with the Stroop Color and Word Test.
It consists of three tasks: reading words, naming colors, and identifying the color in which each word is written, regardless of the word's meaning.
The performance is scored as the number of correct responses completed within the specified time for each condition.
Higher scores indicate better performance.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Anxiety Symptoms
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups.
|
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder Scale (GAD-7).
It consists of seven items evaluating the presence of anxiety-related symptoms.
Scores range from zero to 21, with higher scores indicating greater anxiety severity.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-ups.
|
|
Depressive Symptoms
Zeitfenster: Baseline (2 weeks before intervention) , post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Depressive symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report measure of depression severity based on DSM criteria.
Total scores range from 0 to 27, with higher scores indicate more severe depressive symptoms.
|
Baseline (2 weeks before intervention) , post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
|
Health-related quality of life
Zeitfenster: Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Health-related quality of life will be assessed using a validated cancer-specific quality of life questionnaire, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, version 3 (EORTC QLQ-C30, version 3).
The EORTC QLQ-C30, is a 30-item instrument including global health status/quality of life, functional, and symptom scales.
Scores range from 0 to 100, with higher scores indicating better functioning/global quality of life and worse symptom burden on the symptom scales.
|
Baseline (2 weeks before intervention), post-intervention (2 weeks after), and 3-month and 6-month follow-up.
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Bell ML, Whitehead AL, Julious SA. Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clin Epidemiol. 2018 Jan 18;10:153-157. doi: 10.2147/CLEP.S146397. eCollection 2018.
- Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, Bond CM. Defining Feasibility and Pilot Studies in Preparation for Randomised Controlled Trials: Development of a Conceptual Framework. PLoS One. 2016 Mar 15;11(3):e0150205. doi: 10.1371/journal.pone.0150205. eCollection 2016.
- Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7.
- Fernandes HA, Richard NM, Edelstein K. Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review. Support Care Cancer. 2019 Sep;27(9):3253-3279. doi: 10.1007/s00520-019-04866-2. Epub 2019 May 30.
- Von Ah D, Carpenter JS, Saykin A, Monahan P, Wu J, Yu M, Rebok G, Ball K, Schneider B, Weaver M, Tallman E, Unverzagt F. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2012 Oct;135(3):799-809. doi: 10.1007/s10549-012-2210-6. Epub 2012 Aug 24.
- Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, Winocur G, De Ruiter MB, Castel H. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019 Dec 1;30(12):1925-1940. doi: 10.1093/annonc/mdz410.
- Mackenzie L, Marshall K. Effective non-pharmacological interventions for cancer related cognitive impairment in adults (excluding central nervous system or head and neck cancer): systematic review and meta-analysis. Eur J Phys Rehabil Med. 2022 Apr;58(2):258-270. doi: 10.23736/S1973-9087.21.06898-2. Epub 2021 Sep 9.
- Ercoli LM, Castellon SA, Hunter AM, Kwan L, Kahn-Mills BA, Cernin PA, Leuchter AF, Ganz PA. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav. 2013 Dec;7(4):543-53. doi: 10.1007/s11682-013-9237-0.
- Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for Designing and Evaluating Feasibility Pilot Studies. Med Care. 2022 Jan 1;60(1):95-103. doi: 10.1097/MLR.0000000000001664.
- Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology. 2015 Nov;24(11):1360-7. doi: 10.1002/pon.3769. Epub 2015 Mar 10.
- Von Ah D, Crouch A. Cognitive Rehabilitation for Cognitive Dysfunction after Cancer and Cancer Treatment: Implications for Nursing Practice. Semin Oncol Nurs. 2020 Feb;36(1):150977. doi: 10.1016/j.soncn.2019.150977. Epub 2020 Jan 17.
- Sousa TV, Viveiros V, Chai MV, Vicente FL, Jesus G, Carnot MJ, Gordo AC, Ferreira PL. Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health Qual Life Outcomes. 2015 Apr 25;13:50. doi: 10.1186/s12955-015-0244-2.
- Pfledderer CD, von Klinggraeff L, Burkart S, da Silva Bandeira A, Lubans DR, Jago R, Okely AD, van Sluijs EMF, Ioannidis JPA, Thrasher JF, Li X, Beets MW. Consolidated guidance for behavioral intervention pilot and feasibility studies. Pilot Feasibility Stud. 2024 Apr 6;10(1):57. doi: 10.1186/s40814-024-01485-5.
- Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14;389:e081123. doi: 10.1136/bmj-2024-081123.
- Yang Y, Von Ah D. Cancer-related cognitive impairment: updates to treatment, the need for more evidence, and impact on quality of life-a narrative review. Ann Palliat Med. 2024 Sep;13(5):1265-1280. doi: 10.21037/apm-24-70. Epub 2024 Sep 9.
- Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hrobjartsson A. SPIRIT 2025 statement: updated guideline for protocols of randomized trials. Nat Med. 2025 Jun;31(6):1784-1792. doi: 10.1038/s41591-025-03668-w. Epub 2025 Apr 29.
- Vardy JL, Pond GR, Bell ML, Renton C, Dixon A, Dhillon HM. A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment. J Cancer Surviv. 2023 Dec;17(6):1583-1595. doi: 10.1007/s11764-022-01261-5. Epub 2022 Oct 15.
- Stelwagen J, Meuleman AT, Lubberts S, Steursma G, Kruyt LM, Donkerbroek JW, Meijer C, Walenkamp AME, Lefrandt JD, Rakers SE, Huitema RB, de Jong MAA, Wiegman EM, van den Bergh ACM, de Jong IJ, van Rentergem JAA, Schagen SB, Nuver J, Gietema JA. Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment. Cancers (Basel). 2021 Nov 12;13(22):5675. doi: 10.3390/cancers13225675.
- Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines(R) Insights: Survivorship, Version 1.2022. J Natl Compr Canc Netw. 2022 Oct;20(10):1080-1090. doi: 10.6004/jnccn.2022.0052.
- Saita K, Amano S, Kaneko F, Okamura H. A scoping review of cognitive assessment tools and domains for chemotherapy-induced cognitive impairments in cancer survivors. Front Hum Neurosci. 2023 Feb 20;17:1063674. doi: 10.3389/fnhum.2023.1063674. eCollection 2023.
- Oppegaard KR, Mayo SJ, Armstrong TS, Anguera JA, Kober KM, Miaskowski C. The Multifactorial Model of Cancer-Related Cognitive Impairment. Oncol Nurs Forum. 2023 Feb 17;50(2):135-147. doi: 10.1188/23.ONF.135-147.
- Oliveira AF, Sosa-Napolskij M, Torres A, Queiroz DF, Bartolo A, Sousa H, Monteiro S, Van Dyk K, Ercoli LM, Santos IM. CanCOG(R): Cultural Adaptation of the Evidence-Based UCLA Cognitive Rehabilitation Intervention Program for Cancer Survivors in Portugal. Healthcare (Basel). 2023 Jan 2;11(1):141. doi: 10.3390/healthcare11010141.
- Oliveira AF, Santos IM, Fernandes S, Bem-Haja P, Torres A. Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population. BMC Psychol. 2022 Dec 14;10(1):305. doi: 10.1186/s40359-022-01018-w.
- Oliveira AF, Marques-Fernandes SA, Bartolo A, Bem-Haja P, Torres A, Santos IM. Establishing Diagnostic Cut-Off Scores for the Perceived Cognitive Impairment Subscale of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 in Portuguese Cancer Survivors. Psychooncology. 2025 Sep;34(9):e70278. doi: 10.1002/pon.70278.
- Monteiro, S., Bártolo, A., Torres, A., Pereira, A., & Albuquerque, E. (2019). Examining the construct validity of the Portuguese version of the Patient Health Questionnaire-9 among college students. PSICOLOGIA, 33(2), 1-8. https://doi.org/10.17575/rpsicol.v33i2.1421
- Haywood D, Dauer E, Baughman FD, Lawrence BJ, Rossell SL, Hart NH, O'Connor M. "Is My Brain Ever Going to Work Fully Again?": Challenges and Needs of Cancer Survivors with Persistent Cancer-Related Cognitive Impairment. Cancers (Basel). 2023 Nov 8;15(22):5331. doi: 10.3390/cancers15225331.
- Freitas S, Simoes MR, Alves L, Santana I. Montreal Cognitive Assessment (MoCA): normative study for the Portuguese population. J Clin Exp Neuropsychol. 2011 Nov;33(9):989-96. doi: 10.1080/13803395.2011.589374. Epub 2011 Jul 4.
- Duivon M, Lange M, Binarelli G, Lefel J, Hardy-Leger I, Kiasuwa-Mbengi R, Meric JB, Charles C, Joly F. Improve the management of cancer-related cognitive impairment in clinical settings: a European Delphi study. J Cancer Surviv. 2024 Dec;18(6):1974-1997. doi: 10.1007/s11764-023-01436-8. Epub 2023 Nov 7.
- Dos Santos M, Hardy-Leger I, Rigal O, Licaj I, Dauchy S, Levy C, Noal S, Segura C, Delcambre C, Allouache D, Parzy A, Barriere J, Petit T, Lange M, Capel A, Clarisse B, Grellard JM, Lefel J, Joly F. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial. Cancer. 2020 Dec 15;126(24):5328-5336. doi: 10.1002/cncr.33186. Epub 2020 Sep 30.
- Demos-Davies K, Lawrence J, Seelig D. Cancer related cognitive impairment: a downside of cancer treatment. Front Oncol. 2024 Apr 23;14:1387251. doi: 10.3389/fonc.2024.1387251. eCollection 2024.
- Cherrier MM, Anderson K, David D, Higano CS, Gray H, Church A, Willis SL. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci. 2013 Oct 17;93(17):617-22. doi: 10.1016/j.lfs.2013.08.011. Epub 2013 Sep 5.
- Cavaco, S., Pinto, C., Gonçalves, A., Gomes, F., Pereira, A., & Malaquias, C. (2008). Auditory Verbal Learning Test. Psychologica, 49. https://doi.org/10.14195/1647-8606_49_10
- Cavaco S, Goncalves A, Pinto C, Almeida E, Gomes F, Moreira I, Fernandes J, Teixeira-Pinto A. Auditory Verbal Learning Test in a Large Nonclinical Portuguese Population. Appl Neuropsychol Adult. 2015;22(5):321-31. doi: 10.1080/23279095.2014.927767. Epub 2015 Jan 12.
- Cavaco S, Goncalves A, Pinto C, Almeida E, Gomes F, Moreira I, Fernandes J, Teixeira-Pinto A. Trail Making Test: regression-based norms for the Portuguese population. Arch Clin Neuropsychol. 2013 Mar;28(2):189-98. doi: 10.1093/arclin/acs115. Epub 2013 Jan 7.
- Ahles TA, Root JC. Cognitive Effects of Cancer and Cancer Treatments. Annu Rev Clin Psychol. 2018 May 7;14:425-451. doi: 10.1146/annurev-clinpsy-050817-084903. Epub 2018 Jan 18.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
1. September 2026
Primärer Abschluss (Geschätzt)
Primärer Abschluss
1. Juni 2027
Studienabschluss (Geschätzt)
Studienabschluss
1. Mai 2028
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
29. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
7. August 2026
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
10. August 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
10. August 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
7. August 2026
Zuletzt verifiziert
Zuletzt verifiziert
1. August 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2023.03752.BD (Andere Zuschuss-/Finanzierungsnummer: Foundation for Science and Technology)
- https://doi.org/10.54499/2023 (Andere Kennung: Foundation for Science and Technology)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .